Trial Profile
A Phase 1, Randomized, Observer-blind Study to Compare the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S at a Single Dose of 5*10^10 vp in 2 Different Volumes in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Ad26.COV2 S (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Janssen Vaccines and Prevention B.V
- 21 Dec 2021 Status changed from active, no longer recruiting to completed.
- 06 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2021 Status changed from not yet recruiting to recruiting.